Primary recommendation:
- bobby
- 0
- Posted on
What qualifies as SaMD
SaMD is software intended to perform medical functions without being part of a hardware medical device. Examples include diagnostic algorithms, clinical decision support tools, and mobile apps that monitor vital signs. Because software can change frequently, regulators apply a risk-based approach: higher-risk functions require more stringent evaluation and clinical evidence.
Key regulatory building blocks

– Risk classification: Identify intended use and risk level early. Classification dictates the level of documentation, testing, and oversight required.
– Quality management: Implement a quality management system aligned with recognized standards to manage development, validation, and post-market activities. Standards such as ISO 13485 and processes addressing software lifecycle management are central.
– Software lifecycle and safety: Follow software development and maintenance practices mapped to standards like IEC 62304 and use risk management per ISO 14971 to identify and mitigate hazards.
– Clinical evidence and real-world data: Demonstrate safety and performance proportionate to risk. Where feasible, real-world evidence and validated retrospective datasets can supplement or reduce the need for large prospective studies.
Regulatory pathways and global considerations
Regulatory pathways vary by jurisdiction but share common themes: thorough documentation, traceability, and evidence of clinical performance. Many regulators offer mechanisms tailored to SaMD, including pre-submission engagement and expedited review for innovative, high-need products. For companies targeting multiple markets, plan for divergent requirements (technical documentation, labeling, post-market reporting) and consider harmonization strategies to minimize duplication.
Cybersecurity and data protection
Cybersecurity is a core regulatory expectation for digital products. Requirements typically cover threat analysis, secure design, vulnerability management, and secure update processes.
Data protection and privacy laws add parallel obligations for handling personal health information.
A robust security posture and clear patch/update procedures are both regulatory and market differentiators.
Post-market surveillance and change control
Software updates and algorithm retraining create ongoing regulatory obligations. Post-market surveillance must capture performance metrics, user feedback, and adverse events. Change control processes should classify modifications (minor, substantial, major), assess impact on safety and effectiveness, and trigger regulatory notifications as needed. Leveraging continuous monitoring and user analytics supports proactive risk management.
Regulatory intelligence and strategy
Early regulatory engagement can de-risk development.
Use regulatory intelligence to track guidance updates and enforcement trends across markets. Establish a regulatory roadmap that aligns product development milestones with submission requirements and clinical evidence generation. Consider leveraging regulatory consultants or partnerships when entering highly regulated markets.
Practical tips for submissions
– Start classification and clinical planning early.
– Maintain traceability from requirements to verification and validation.
– Provide clear risk assessments and mitigation plans.
– Document cybersecurity controls and update mechanisms.
– Use real-world data where appropriate, with transparent methodology.
A pragmatic, risk-based regulatory strategy for SaMD balances rigorous evidence and quality practices with fast, iterative software development. Companies that embed regulatory thinking into product design and lifecycle management reduce surprises, accelerate market access, and build lasting trust with regulators and users.